Tanya Siddiqi, MD of @cityofhope discusses the updated results from transcend CLL 004, a Phase 1/2 study including patients with high-risk disease treated with ibrutinib.
Transcend CLL 004 Update #ASH19 @cityofhope
Tanya Siddiqi, MD of @cityofhope discusses the updated results from transcend CLL 004, a Phase 1/2 study including patients with high-risk disease treated with ibrutinib.